Company news
Minerva Neurosciences, Inc news in 2020
Minerva Neurosciences, Inc's news releases, calls and decks from 2020, newest first.
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
November 30, 2020
Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates
November 1, 2020
Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020
October 25, 2020
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
August 2, 2020
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
June 30, 2020
REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
May 31, 2020
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
May 28, 2020
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
May 3, 2020
Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates
March 8, 2020
Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020
March 1, 2020
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
February 4, 2020
Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
January 5, 2020
Calls in 2020
Decks in 2020
- Technical Presentation (June 2020)
Technical · 26 slides · Jun 5, 2020
- Technical Presentation (April 2020)
Technical · 23 slides · Apr 1, 2020